Dutasteride in Androgenetic Alopecia: An Update.
Level 5 - mechanism / opinion, no new human data
Narrative review of previously published literature without systematic review or meta-analytic methodology
PubMed 28294070 · doi:10.2174/1574884712666170310111125
What was done
The authors conducted a narrative literature search across Medline/PubMed, Google Scholar, and Scopus using the keywords "dutasteride" and "dutasteride in androgenetic alopecia" to review original and review articles. They summarized the pharmacology, mechanism as a dual type-1 and type-2 5-α-reductase inhibitor, pharmacokinetics, side effect profile, and clinical trial outcomes of dutasteride compared to finasteride.
What was found
The abstract reports no numerical data, effect estimates, or statistical values. It qualitatively states that multiple randomized, double-blind, placebo-controlled trials and meta-analyses show dutasteride is effective for androgenetic alopecia, with most reviewed studies reporting superior efficacy compared to finasteride and comparable rates of adverse effects.
Why it matters
While finasteride and minoxidil are standard approved treatments, dual 5-α-reductase inhibition with dutasteride may offer an alternative or more efficacious pharmacological option for managing androgenetic alopecia.
Limits
The paper is an unsystematic narrative review with no formal quality appraisal, risk-of-bias evaluation, or quantitative data synthesis. The abstract does not specify the number of included studies, sample sizes, patient demographics, drug dosages, follow-up durations, or specific adverse event rates.
Cited by
- supports Dihydrotestosterone (DHT) is a more potent androgen than testosterone and drives androgenetic alopecia.